Drug
Bupivacaine Liposome
Bupivacaine Liposome: highest development phase Post-Market, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bupivacaine Liposome Injection NCT06344091 | Post-Market | Local Analgesia Via Infiltration |
Latest
No recent events.
Follow Bupivacaine Liposome on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.